Use of TXA to Prevent Postpartum Hemorrhage (TAPPH-1 Trial)

Phase 2

Waitlist Available

Led By Asim Q Alam, MD, FRCPC

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 months

Summary

This trial is being done to see if the prophylactic use of TXA can safely reduce the rate of PPH and the need for blood transfusions in women having a cesarean section.

Eligible Conditions

Postpartum Hemorrhage

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of patients receiving study intervention

Secondary study objectives

Composite number of clinical events

Duration of study to recruit 58 participants

Incidence of PPH in study participants

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: TXA (1g)Experimental Treatment1 Intervention

For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site

Group II: Placebo (0.9% saline)Placebo Group1 Intervention

For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site

Do I qualify?Apply below to find out